These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33491565)

  • 1. Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension.
    Gray Z; Tu W; Chertow GM; Bhalla V
    Am J Physiol Renal Physiol; 2021 Mar; 320(3):F325-F335. PubMed ID: 33491565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension and the expanding role of aldosterone.
    Mackenzie SM; Connell J
    Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
    Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
    Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.
    Viazzi F; Leoncini G; Pontremoli R
    High Blood Press Cardiovasc Prev; 2013 Dec; 20(4):273-82. PubMed ID: 24092648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salt, the renin-angiotensin-aldosterone system and resistant hypertension.
    Shimosawa T
    Hypertens Res; 2013 Aug; 36(8):657-60. PubMed ID: 23912973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and clinical investigations in patients with low-renin hypertension.
    Mackenzie IS; Brown MJ
    Clin Exp Nephrol; 2009 Feb; 13(1):1-8. PubMed ID: 18704622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
    Kawarazaki W; Fujita T
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone and refractory hypertension.
    Nyirenda MJ; Padfield PL
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):213-8. PubMed ID: 17940442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Aldosterone in Obesity-Related Hypertension.
    Kawarazaki W; Fujita T
    Am J Hypertens; 2016 Apr; 29(4):415-23. PubMed ID: 26927805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a new dawn for selective mineralocorticoid receptor antagonism?
    Luther JM
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):456-61. PubMed ID: 24992570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
    Chrysant SG; Chrysant GS
    Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug mechanisms to help in managing resistant hypertension in obesity.
    Jansen PM; Danser JA; Spiering W; van den Meiracker AH
    Curr Hypertens Rep; 2010 Aug; 12(4):220-5. PubMed ID: 20532698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.
    Lincevicius GS; Shimoura CG; Nishi EE; Perry JC; Casarini DE; Gomes GN; Bergamaschi CT; Campos RR
    Am J Hypertens; 2015 Sep; 28(9):1083-90. PubMed ID: 25628418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.